Drugs / Paclitaxel-albumin
Paclitaxel-albumin
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06953323 | Jul 2025 → Jun 2029 expected | neoplasm | Wigen Biomedicine Technology (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 210 trials | ||||||
| Phase 2 | NCT06406426 | May 2024 → May 2025 overdue | gastroesophageal junction adenocarcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT06100497 | Oct 2023 → Oct 2025 overdue | head and neck squamous cell carcinoma | Beijing Tongren Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06718205 | Mar 2023 → Sep 2025 overdue | esophageal cancer | The First Affiliated Hospital of Zhengzhou University | Recruiting | No outcome recorded |
| Phase 2 | NCT05585580 | Mar 2023 → Apr 2026 overdue | gastroesophageal adenocarcinoma | Qilu Hospital of Shandong University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05982301 | Feb 2023 → Jan 2025 | chemotherapy-induced toxicity, gastric cancer | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT06030934 | Oct 2022 → Nov 2024 | gastroesophageal junction adenocarcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT05322499 | Apr 2022 → Apr 2023 | esophageal squamous cell carcinoma | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05807542 | Mar 2022 → Sep 2023 | esophageal squamous cell carcinoma | Shanghai Zhongshan Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04844385 | Feb 2021 → Dec 2024 | esophageal squamous cell carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT03585062 | Nov 2017 → Jul 2019 | malignant pancreatic neoplasm | Zhejiang Provincial People's Hospital | Terminated | No outcome recorded |
| Comparator or background therapy7 trials | ||||||
| Phase 2 | NCT07234877 Background | Nov 2026 → Jan 2032 expected | non-small cell lung carcinoma | European Organisation for Research and Treatment of Cancer - EORTC | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06412471 Background | Jul 2024 → Jul 2025 | — | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT06955156 Background | Jul 2023 → May 2025 overdue | triple-negative breast carcinoma | QIAO LI | Recruiting | No outcome recorded |
| Phase 2 | NCT05738434 Background | Mar 2023 → Sep 2025 overdue | digestive system carcinoma | The First Affiliated Hospital of Zhengzhou University | Recruiting | No outcome recorded |
| Phase 2 | NCT04108013 Comparator | Oct 2019 → Jul 2021 | autoimmune pulmonary disease due to PD-1 deficiency, non-small cell lung carcinoma | Xuanwu Hospital, Beijing | Unknown | No outcome recorded |
| Phase 2 | NCT04172259 Background | Jan 2019 → Sep 2023 overdue | breast cancer | Sun Yat-sen University | Active not recruiting | No outcome recorded |
| — | NCT04181645 Background | Jun 2019 → Dec 2021 | pancreatic ductal adenocarcinoma | RenJi Hospital | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Paclitaxel-albumin | “Paclitaxel-albumin 250mg/m2 ivgtt d1 Q3w or 125mg/m2 ivgtt d1,d8 Q3w” NCT06955156 ↗17“paclitaxel-albumin 150\~180 mg/m2, i.v. d1,q3w” NCT05738434 ↗ |
| Known as | Paclitaxel-albumin Injection | “Paclitaxel-albumin Other Name: Paclitaxel-albumin Injection” NCT04181645 ↗ |
| Known as | Protein bound paclitaxel | “Protein bound paclitaxel is a novel paclitaxel combined of paclitaxel and albumin by nanotechnology” NCT03585062 ↗ |
| Route | Intravenous | “intravenous infusion for 30 minutes” NCT03585062 ↗ |